Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 22, 2019
Pharmacy Choice - Pharmaceutical News - Actavis infringes Orexo's long term Zubsolv US patent '330 - January 22, 2019

Pharmacy News Article

 1/11/19 - Actavis infringes Orexo's long term Zubsolv US patent '330

Uppsala, Sweden - January 11, 2019 - Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the United States District Court for the District of Delaware has issued a final, non-appealable judgement that Actavis's generic Zubsolv products infringe Orexo's US patent No. 8,940,330. The judgement will prevent Actavis from commercializing their infringing generic Zubsolv products in the US until after September 18, 2032.

The infringement judgement now issued by the District Court follows from the decision from the US Court of Appeals for the Federal Circuit on September 10, 2018, that the `330 patent is valid. The infringement judgement involves all dosage strengths of Actavis's generic Zubsolv products. As a result of the favourable infringement judgement, Orexo's lawsuits against Actavis involving US Patent Nos. 9,259,421 and 9,439,900, also protecting Zubsolv in the US until September 18, 2032, have been withdrawn.

This infringement judgement does not relate to the litigation against Actavis where Orexo alleges that Actavis's generic versions of Suboxone and Subutex tablets infringe Orexo's US Patent No. 8,454,996.

"Although expected, I am very pleased that we now have a final judgement preventing Actavis from commercializing its generic Zubsolv products in the US until September 2032. It has been an extraordinarily long process and I want to thank my team, the Board of Directors and the shareholders who never doubted we would succeed. We are now looking forward to focus on expanding our commercial platform to leverage scale and increase revenues."
said Nikolaj Srensen, President and CEO, Orexo AB.

For further information, please contact:

Orexo AB (publ.)
Nikolaj Srensen, Lena Wange, IR and Communications Manager
President and CEO

Tel: +46 (0)18 780 Tel: +46 (0)18 780 88 00
88 00
E-mail: E-mail: ir@orexo.com
ir@orexo.com

About Orexo

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.

The information was submitted for publication at8:00 am CET on January 11, 2019

http://news.cision.com/orexo/r/actavis-infringes-orexo-s-long-term-zubsolvus-patent330,c2715647

https://mb.cision.com/Main/694/2715647/975081.pdf



(c) 2019 Cision. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jan 22: Medication Use During Pregnancy & Lactation
Last Chance
Jan 23: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Jan 24: COPD Update for Pharmacy Professionals
Jan 28: From Memory to Alzheimer’s - Supporting Memory With Lifestyle Medicine
Jan 29: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415